Literature DB >> 6467638

Effect of metoclopramide in plasma vasopressin in man.

K Nomura, F Kurimoto, H Demura, H Sakurai, T Nomura, K Zibiki, M Naruse, N Kanai, K Shizume.   

Abstract

The effect of metoclopramide, a dopamine blocker, on arginine vasopressin (AVP) secretion was investigated in normal males. After a bolus injection of metoclopramide (10 mg), all subjects (n = 7) demonstrated an increase of 80.3% (from 0.71 +/- 0.12 (Mean +/- S.E.) to 1.28 +/- 0.24 pg/ml, P less than 0.005) in plasma AVP at 15 min. In controls (n = 7) plasma AVP levels did not change after saline injection (2 ml). Because plasma osmolality and blood pressure did not change, the elevation of plasma AVP levels induced by treatment with metoclopramide may be due to its central effect as a dopamine inhibitor. Although plasma AVP levels increased again at 90 and 120 min after a bolus injection of metoclopramide, accompanying falls in blood pressure (4-5%) make the interpretation concerning the contribution of dopamine to AVP secretion in a late phase uncertain. In summary, plasma AVP levels were shown to be significantly increased by a metoclopramide bolus, suggesting that AVP secretion is under tonic inhibition by dopamine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6467638     DOI: 10.1111/j.1365-2265.1984.tb03450.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  1 in total

1.  Different effects of metoclopramide and domperidone on arginine-vasopressin secretion in man.

Authors:  P Chiodera; R Volpi; R Delsignore; C Marchesi; G Salati; L Camellini; G Rossi; V Coiro
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.